Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Q&A: Scoring Drug Supply Chains for Resilience, Not Just Price

4 August 2026 · By · Wire by Fusion42

Published

4 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at pharmaceuticalcommerce.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

The National Fragility Index (NFI) integrates multiple risk factors to score drug supply chains for resilience rather than price alone, enabling procurement teams and policymakers to identify weak points and prioritize diversification and domestic manufacturing investments to reduce shortage risks.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You must add resilience scoring to your drug procurement strategy to outsmart the lowest-price trap that risks supply failures. This tool opens a door to reduce shortages and prove investments in domestic manufacturing actually cut disruption risks.

◆ Coverage

1 source · 4 Aug 2026

◆ Related on Wire

◆ Topics

Healthdrug-supply-chainresilience-scoringprocurement-strategypharma-shortagesdomestic-manufacturing